CNS drugs

The clinical drug effects of 5-MeO-DMT from toad venom in hard-to-treat depression

Updated

Abstract

In a pivotal phase 2b trial, inhaled GH001 reduced depression scores by 15.5 points on the Montgomery-Åsberg Depression Rating Scale by day 8 compared to placebo.

  • Mebufotenin acts as a non-selective serotonin agonist, with high affinity for the 5-HT1A receptor.
  • The compound's clearance is primarily managed by monoamine oxidase A, and its metabolite bufotenine shows a similar receptor profile to mebufotenin.
  • In the trial, 57.5% of patients receiving GH001 achieved remission by day 8, whereas none in the placebo group did.
  • Most patients (97.5%) were ready for discharge within 1 hour after treatment.
  • No serious treatment-related adverse events were reported, suggesting a favorable safety profile.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free